News Ipsen London S.E.

Stocks

0MH6

FR0010259150

Pharmaceuticals

Market Closed - London S.E. 11:30:00 2026-08-28 EDT			5-day change	1st Jan Change
163.55 ^EUR	-3.05%		-0.09%	+37.78%

08-21	Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc.	CI
08-21	Ipsen Wraps Up Purchase of US-based Kartos Therapeutics	MT

All News

Mentions Relevance

08-24	IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026	GL
08-21	Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc.	CI
08-21	Ipsen Wraps Up Purchase of US-based Kartos Therapeutics	MT
08-21	Ipsen closes the acquisition of Kartos Therapeutics
08-21	Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline	GL
08-17	IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026	GL
08-17	Kepler Cheuvreux Boosts Ipsen PT, Maintains Hold Rating	MT
08-10	IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026	GL
08-04	Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration	CI
08-03	IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026	GL
08-03	Jefferies Downgrades Ipsen to Underperform, Boosts PT	MT
07-31	Ipsen S.A., H1 2026 Earnings Call, Jul 30, 2026
07-30	Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)	GL
07-30	Ipsen: Another quarterly beat; 2026 guidance upgraded
07-30	Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Ipsen raises its full-year targets
07-30	Ipsen Raises FY26 Sales Growth Outlook	MT
07-30	Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance	GL
07-29	Ipsen nominates Catherine Bradley to its Board of Directors as independent Director	GL
07-29	Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026	CI
07-27	IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026	GL
07-24	Ipsen Provides Update On Phase III BOLD Trial In Biliary Atresia	CI
07-24	Ipsen Says Phase 3 Trial of Bylvay in Biliary Atresia Misses Primary Endpoint	MT
07-24	Ipsen provides update on Phase III BOLD trial in biliary atresia	GL
07-22	Ipsen Closes Purchase of Potravitug Developer Memo Therapeutics	MT